Testing beyond BRCA in breast and ovarian cancers was the focus of a recent article in JAMA Oncology. The conclusion was:
In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone. Multigene testing in this setting is likely to alter near-term cancer risk assessment and management recommendations for mutation-affected individuals across a broad spectrum of cancer predisposition genes.
“Basket Study” Targets Mutation Not Cancer Type, Widens Patient Drug Trial Access
Memorial Sloan Kettering Cancer Center (MSK) just published results in the New England Journal of Medicine for a basket study for an early Phase II study, led by MSK Physician-in-Chief and Chief Medical Officer José Baselga, that looked at the effect of vemurafenib (Zelboraf) in multiple nonmelanoma BRAFV600-mutated cancers in 122 patients from 23 centers around the world. What is unique about this design is it focused on mutation rather than histology. This makes it far more likely to pick up activity in a host of tumors with this mutation more quickly than a traditional trial schema, where each tumor and mutation would be tested individually.